Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

R0145000

Ramipril

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Tritace, [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C23H32N2O5
Numéro CAS:
87333-19-5
Poids moléculaire :
416.51
Numéro MDL:
MFCD00865775
Code UNSPSC :
41116107
ID de substance PubChem :
329823973
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

ramipril

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

O=C(N1[C@](CCC2)([H])[C@]2([H])C[C@H]1C(O)=O)[C@H](C)N[C@H](C(OCC)=O)CCC3=CC=CC=C3

InChI

1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1

Clé InChI

HDACQVRGBOVJII-JBDAPHQKSA-N

Informations sur le gène

human ... ACE(1636)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ramipril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Angiotensin converting enzyme (ACE) inhibitor.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1598303

Ramipril, United States Pharmacopeia (USP) Reference Standard

1598314

Ramipril Related Compound A, United States Pharmacopeia (USP) Reference Standard

1598347

Ramipril Related Compound D, United States Pharmacopeia (USP) Reference Standard

R0145005

Ramipril impurity A, European Pharmacopoeia (EP) Reference Standard

R0145020

Ramipril impurity D, European Pharmacopoeia (EP) Reference Standard

R0145010

Ramipril impurity B, European Pharmacopoeia (EP) Reference Standard

R0145015

Ramipril impurity C, European Pharmacopoeia (EP) Reference Standard

1598323

Ramipril Related Compound B, United States Pharmacopeia (USP) Reference Standard

1598338

Ramipril Related Compound C, United States Pharmacopeia (USP) Reference Standard

BP751

Ramipril, British Pharmacopoeia (BP) Reference Standard

BP754

Ramipril impurity K, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H360FD

Classification des risques

Repr. 1B

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Carolina De Ciuceis et al.
Hypertension (Dallas, Tex. : 1979), 64(4), 717-724 (2014-07-02)
Structural alterations of subcutaneous small-resistance arteries are associated with a worse clinical prognosis in hypertension and non-insulin-dependent diabetes mellitus. The effects of the direct renin inhibitor aliskiren on microvascular structure were never previously evaluated. Therefore, we investigated the effects of
April D Vuong et al.
The Annals of pharmacotherapy, 37(3), 412-419 (2003-03-18)
To evaluate the effectiveness of ramipril in the prevention and treatment of cardiovascular disease and determine its need for inclusion on a formulary. A MEDLINE and PubMed database search was conducted (1987-May 2002). Only journals written in the English language
J E Frampton et al.
Drugs, 49(3), 440-466 (1995-03-01)
Ramipril is a second generation angiotensin converting enzyme (ACE) inhibitor. Like enalapril, it is a prodrug and is hydrolysed in vivo to release the active metabolite, ramiprilat, which has a long elimination half-life, permitting once-daily administration. The antihypertensive efficacy of
W Linz et al.
Zeitschrift fur Kardiologie, 83 Suppl 4, 53-56 (1994-01-01)
ACE inhibitors induce an increase in kinin levels with subsequent release of nitric oxide (NO) and prostacyclin, as shown in cultured endothelial cells and isolated rat hearts. Isolated perfused working rat hearts continuously release kinins and prostacyclin. During ischemia after
Antonios Douros et al.
American journal of hypertension, 26(9), 1070-1075 (2013-06-12)
Ramipril, an inhibitor of the angiotensin-converting enzyme (ACEI), is a drug commonly used in the therapy of hypertension. ACEI-induced hepatotoxicity is rare, and most of the reported cases are associated with captopril. Here, we present the first case of ramipril-induced
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique